$0.73 Earnings Per Share Expected for TearLab Corporation (TEAR) This Quarter

Paterniano Del Favero
Luglio 23, 2017

Equity Research firms now have a positive stance on shares of TearLab Corporation (NASDAQ:TEAR). TearLab Corporation earned a news impact score of -0.12 on Accern's scale. Equities analysts forecast that TearLab Corporation will post ($2.82) EPS for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($1.39) per share. About 343,843 shares traded or 49588.29% up from the average.

TearLab Corporation (NASDAQ:TEAR)'s stock has performed at -35.76%. This is based on the research brokerage reports taken into consideration by Thomson Reuters. The business had revenue of $6.70 million for the quarter, compared to analyst estimates of $7.02 million. The firm's revenue was down 1.5% on a year-over-year basis. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Accern also gave media coverage about the medical research company an impact score of 45.8948692012763 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Zacks Investment Research cut TearLab Corporation from a "buy" rating to a "hold" rating in a research note on Tuesday, May 16th. The stock presently has a consensus rating of "Buy" and a consensus price target of $5.05. HC Wainwright reissued a "buy" rating and issued a $4.00 target price on shares of TearLab Corporation in a research note on Tuesday, May 16th. During the same quarter in the previous year, the company earned ($0.21) EPS.

"WARNING: "-$0.73 Earnings Per Share Expected for TearLab Corporation (TEAR) This Quarter" was first reported by Markets Daily and is the property of of Markets Daily.

Headlines about TearLab Corporation (NASDAQ:TEAR) have trended somewhat negative recently, according to Accern Sentiment Analysis. If you are accessing this report on another publication, it was stolen and reposted in violation of USA & worldwide copyright laws. The company's market capitalization is $10.09 million.

Current levels places TearLab Corporation (NASDAQ:TEAR)'s stock about -4.48% from the 50-day high and 103.37% away from the 50-day low. While the stock price moved along with the volume change, shares are touching $3.23 at the time of writing.

TearLab Corporation is an in-vitro diagnostic company. The Firm has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Altre relazioni OverNewsmagazine

Discuti questo articolo